These findings affirm the hepato-regenerative properties of chimeric FGF21/HGFR within AML12 cells, opening novel avenues for therapeutic exploration in NAFLD. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.